Survival of patients with advanced Non Small Cells Lung Cancer and EGF concentration in sera highest than 870 pg/mL that receive CIMAvax EGF(C) as maintenance therapy.
Phase of Trial: Phase III
Latest Information Update: 26 Aug 2016
At a glance
- Drugs BV NSCLC 001 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 Aug 2016 New trial record